209 related articles for article (PubMed ID: 30701334)
1. Clinical relevance of gene expression in localized and metastatic prostate cancer exemplified by FABP5.
Nitschke K; Erben P; Waldbillig F; Abdelhadi A; Weis CA; Gottschalt M; Wahby S; Nuhn P; Boutros M; Michel MS; von Hardenberg J; Worst TS
World J Urol; 2020 Mar; 38(3):637-645. PubMed ID: 30701334
[TBL] [Abstract][Full Text] [Related]
2. SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
Hernández-Llodrà S; Segalés L; Safont A; Juanpere N; Lorenzo M; Fumadó L; Rodríguez-Vida A; Cecchini L; Bellmunt J; Lloreta-Trull J
Prostate; 2019 Jul; 79(10):1156-1165. PubMed ID: 31090082
[TBL] [Abstract][Full Text] [Related]
3. Determination of TMPRSS2-ERG, SPOP, FOXA1, and IDH1 prostate cancer molecular subtypes in Colombian patients and their possible implications for prognosis.
Montero-Ovalle W; Sanabria-Salas MC; Mesa-López de Mesa J; Varela-Ramírez R; Segura-Moreno YY; Sánchez-Villalobos SA; Nuñez-Lemus M; Serrano ML
Cell Biol Int; 2023 May; 47(5):1017-1030. PubMed ID: 36740223
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA
J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
[TBL] [Abstract][Full Text] [Related]
5. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene.
Ribeiro FR; Paulo P; Costa VL; Barros-Silva JD; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
PLoS One; 2011; 6(7):e22317. PubMed ID: 21814574
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
[TBL] [Abstract][Full Text] [Related]
7. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA
Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase
Waldbillig F; Nitschke K; Abdelhadi A; von Hardenberg J; Nuhn P; Nientiedt M; Weis CA; Michel MS; Erben P; Worst TS
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575490
[TBL] [Abstract][Full Text] [Related]
9. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
Saramäki OR; Harjula AE; Martikainen PM; Vessella RL; Tammela TL; Visakorpi T
Clin Cancer Res; 2008 Jun; 14(11):3395-400. PubMed ID: 18519769
[TBL] [Abstract][Full Text] [Related]
10. Molecular and Clinicopathological Aspects of Prostate Cancer in Bulgarian Probands.
Tsvetkova A; Todorova A; Todorov T; Georgiev G; Drandarska I; Mitev V
Pathol Oncol Res; 2015 Sep; 21(4):969-76. PubMed ID: 25753984
[TBL] [Abstract][Full Text] [Related]
11. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.
Darnel AD; Lafargue CJ; Vollmer RT; Corcos J; Bismar TA
Cancer Biol Ther; 2009 Jan; 8(2):125-30. PubMed ID: 19029822
[TBL] [Abstract][Full Text] [Related]
12. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion.
Gerashchenko GV; Mevs LV; Chashchina LI; Pikul MV; Gryzodub OP; Stakhovsky EO; Kashuba VI
Exp Oncol; 2018 Jun; 40(2):101-108. PubMed ID: 29949537
[TBL] [Abstract][Full Text] [Related]
13. FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.
Tsourlakis MC; Eleftheriadou A; Stender A; Weigand P; Grupp K; Hube-Magg C; Kluth M; Schroeder C; Steurer S; Hinsch A; Luebke A; Angerer A; Wittmer C; Friedrich E; Göbel C; Büscheck F; Heinzer H; Graefen M; Simon R; Sauter G; Wilczak W; Minner S; Schlomm T; Jacobsen F
Carcinogenesis; 2017 Dec; 38(12):1180-1187. PubMed ID: 29029032
[TBL] [Abstract][Full Text] [Related]
14. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
[TBL] [Abstract][Full Text] [Related]
15. Detection of prostate-specific antigen RNA before and after radical retropubic prostatectomy and transurethral resection of the prostate using "Light-Cycler"-based quantitative real-time polymerase chain reaction.
Straub B; Müller M; Krause H; Schrader M; Goessl C; Heicappell R; Miller K
Urology; 2001 Nov; 58(5):815-20. PubMed ID: 11711374
[TBL] [Abstract][Full Text] [Related]
16. [Relationship between TMPRSS2: ERG and the pathological grade of prostate cancer].
Yi FX; Li H; Wei Q; Li X; Zeng H
Zhonghua Nan Ke Xue; 2015 Oct; 21(10):887-91. PubMed ID: 26665675
[TBL] [Abstract][Full Text] [Related]
17. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
18. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
Hernández-Llodrà S; Segalés L; Juanpere N; Marta Lorenzo T; Salido M; Nonell L; David López T; Rodríguez-Vida A; Bellmunt J; Fumadó L; Cecchini L; Lloreta-Trull J
Prostate; 2021 Dec; 81(16):1267-1277. PubMed ID: 34533858
[TBL] [Abstract][Full Text] [Related]
19. Underexpression of MMP-2 and its regulators, TIMP2, MT1-MMP and IL-8, is associated with prostate cancer.
Reis ST; Antunes AA; Pontes-Junior J; Sousa-Canavez JM; Dall'Oglio MF; Piantino CB; Cruz JA; Morais DR; Srougi M; Leite KR
Int Braz J Urol; 2012; 38(2):167-74. PubMed ID: 22555040
[TBL] [Abstract][Full Text] [Related]
20. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA
Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]